Systemic light chain amyloidosis

The PBS subsidises daratumumab for patients with newly diagnosed systemic light chain amyloidosis.

Please note: You’ll get an immediate assessment when you request PBS authorities online.

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with daratumumab under the National Health Act 1953, section 85 for patients with newly diagnosed systemic light chain amyloidosis.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing daratumumab.

Treatment specifics

To be eligible for PBS-subsidised treatment with daratumumab, patients must be treated by a haematologist (this does not exclude treatment via a multidisciplinary team, but the PBS authority application must be written by the treating haematologist).

Authority applications

Applying for initial treatment

Applications for initial authority approval to prescribe PBS-subsidised daratumumab to treat newly diagnosed systemic light chain amyloidosis can be made either in:

All written applications must include:

Applying for continuing treatment

Applications for continuing authority approval to prescribe PBS-subsided daratumumab to treat newly diagnosed systemic light chain amyloidosis can be made either:

More information

Call the PBS authority approvals line for more information.

Page last updated: 19 June 2024.
QC 63898